Obestatin

What is Obestatin?

Obestatin is a 23-amino-acid peptide proposed in 2005 by Jian V. Zhang, Pei-Gen Ren, Aaron J. W. Hsueh, and colleagues at Stanford University as a previously unrecognized ghrelin-opposing hormone encoded by the same preproghrelin (GHRL) gene. Their Science paper reported that ghrelin and obestatin are both cleaved from the 117-residue preproghrelin precursor — ghrelin from residues 24-51 and obestatin from residues 76-98 — and that obestatin produces effects opposite to those of ghrelin: reduced food intake, reduced gastric emptying, and reduced body weight gain in rodents. The paper further proposed that obestatin signals through the orphan GPCR GPR39, identifying it as the cognate receptor through reverse pharmacology screening. The 2005 publication generated immediate excitement because it appeared to deliver the rare combination of a novel anorectic hormone, a paired stimulatory/inhibitory peptide system within a single gene, and an actionable receptor target — and obestatin was widely promoted as a candidate anti-obesity therapeutic. Within two to three years, however, multiple independent laboratories had failed to replicate the central food-intake findings: Gourcerol and colleagues (UCLA, Obesity 2007), Nogueiras and colleagues (Endocrinology 2007), and others reported that exogenous obestatin produced no significant effect on food intake or body weight in lean or obese rodents under a range of administration paradigms. The proposed obestatin/GPR39 receptor identification was also contested: Lauwers and colleagues, Holst and colleagues, and Tremblay and colleagues all reported that obestatin does not bind or activate GPR39 in their assays, and the receptor was eventually deorphanized as a zinc-sensing GPCR. As of 2026 the existence of obestatin as a peptide processed from preproghrelin is well established, but its physiological role as an anorectic hormone, its receptor, and its therapeutic potential remain disputed. Obestatin is studied as an experimental peptide with possible roles in gastrointestinal motility, pancreatic beta-cell function, cardiovascular biology, sleep, and thirst (Samson and colleagues), but no obestatin product has been clinically developed.

What Obestatin Is Investigated For

Obestatin is a contested-physiology and academic-controversy topic, not a peptide consumers take. Its translational status is unique among gut hormones: a high-profile Science paper in 2005 proposed obestatin as a ghrelin-opposing anorectic hormone with an identified receptor (GPR39), and within three years multiple independent laboratories had failed to replicate the food-intake findings (Gourcerol, Nogueiras, and others) and contested the receptor identification (Lauwers, Holst, Tremblay). The honest framing is that obestatin exists — its processing from preproghrelin is biochemically established, it circulates, and it has measurable effects in some assay systems — but its identity as a physiological ghrelin antagonist on food intake and as a GPR39 ligand is not supported by the broader literature. Effects that have been replicated more reliably include modest gastrointestinal-motility actions, central inhibition of water intake (Samson and colleagues, 2007), cytoprotective effects on pancreatic beta cells in some preclinical models, and cardiovascular effects in ex vivo preparations. The original anti-obesity premise has not survived independent scrutiny, no obestatin product has been clinically developed, and the field consensus through the 2010s and 2020s is that obestatin is a peptide of uncertain physiological significance rather than a missed therapeutic opportunity. The controversy remains a teaching example in peptide endocrinology for the importance of reproducibility, independent receptor characterization, and skepticism toward press-release-driven novel-hormone claims.

History & Discovery

Obestatin was reported in November 2005 by Jian V. Zhang, Pei-Gen Ren, Aaron J. W. Hsueh, and colleagues at Stanford University in a Science paper titled 'Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake.' The peptide was identified through a bioinformatic search for additional mature peptides processed from the 117-residue preproghrelin precursor, leveraging the recognition that preproghrelin appeared too long to encode only ghrelin. The team reported a 23-amino-acid C-terminally amidated peptide (residues 76-98 of preproghrelin) that they named 'obestatin' for its proposed role in 'obesity statin' (suppressing food intake and body weight). The same paper reported anorectic effects in rodents and identified the orphan receptor GPR39 as the cognate obestatin receptor through reverse pharmacology screening. The publication generated immediate excitement because it appeared to deliver a paired stimulatory/inhibitory peptide system within a single gene (a rare biological architecture), a novel anorectic hormone, and an actionable receptor target — and obestatin was widely promoted in trade and consumer media as a candidate anti-obesity therapeutic. The failure-to-replicate trajectory developed quickly. By 2007, multiple independent laboratories had reported null findings on the central food-intake claim. Guillaume Gourcerol, Yvette Tache, and colleagues at UCLA reported in Obesity that exogenous obestatin did not influence food intake or body weight in lean or obese rodents under a range of administration paradigms, dose ranges, and feeding states. Ruben Nogueiras, Matthias Tschop, and colleagues reported in Endocrinology that obestatin had no consistent effect on energy balance or growth hormone secretion. Nicolas Chartrel and colleagues published a Science Brevia commentary in 2007 explicitly questioning the obestatin-as-anorectic-hormone hypothesis. The receptor identification was contested in parallel: Erik Lauwers and colleagues, Birgitte Holst and colleagues, and others reported that obestatin does not bind or activate GPR39 in their assays, and GPR39 was eventually deorphanized as a zinc-sensing receptor with no validated obestatin pharmacology in independent laboratories. The Stanford group and several others maintained the original obestatin framing, publishing additional papers on obestatin's effects in pancreatic beta cells (the Granata/Ghigo group in Turin produced an extensive cytoprotection program), cardiovascular biology, sleep, and stress responses. The overall scientific consensus through the 2010s and 2020s, however, has converged on the view that obestatin exists as a peptide processed from preproghrelin but has uncertain physiological significance — and that the original 2005 framing of obestatin as a paired ghrelin antagonist on food intake is not supported by the broader literature. The translational pipeline that the original paper appeared to launch did not materialize: no obestatin product or selective obestatin-pathway agonist has reached clinical development. Obestatin remains an instructive case study in peptide-endocrinology reproducibility. The 2005 Science paper has been cited thousands of times — both for the original proposal and for the subsequent contested replications — and it is regularly used in scientific-methodology coursework as an example of why independent receptor identification and independent in vivo replication are essential before novel-hormone claims enter the literature as established. As of 2026, obestatin is best understood as a peptide of disputed physiological role rather than as the anti-obesity therapeutic it was initially promoted to be.

How It Works

Obestatin is a small peptide cut from the same gene that makes ghrelin (the famous hunger hormone). When researchers at Stanford reported it in 2005, they said obestatin did the opposite of ghrelin — suppressing appetite and slowing the stomach. That would have been an exciting weight-loss target, and the paper got a lot of attention. The problem is that other laboratories tried the same experiments and could not get the same results. Within three years, multiple independent groups reported that obestatin had no effect on feeding in their rodents, and the receptor that Stanford proposed (GPR39) was disputed too. Today obestatin is mostly remembered as a cautionary tale about the importance of independent replication. It exists as a peptide, but what it does — and whether it matters physiologically — is still unclear.

Obestatin is a 23-amino-acid linear peptide (sequence FNAPFDVGIKLSGVQYQQHSQAL-NH2 in humans, with C-terminal amidation) cleaved from the 117-residue preproghrelin precursor encoded by the GHRL gene on human chromosome 3p25. The same precursor produces ghrelin (residues 24-51, with octanoyl-serine-3 modification by ghrelin O-acyltransferase, GOAT) and obestatin (residues 76-98). Both peptides are produced primarily by enteroendocrine X/A-like cells of the gastric oxyntic mucosa, with secondary production in the small intestine, pancreatic alpha cells, and other tissues. The biochemical processing of obestatin from preproghrelin is established and is not the controversial part of obestatin biology. The controversy concerns three claims from the 2005 Science paper. First, that obestatin reduces food intake and body weight gain in rodents — replicated by some authors but reported as null by Gourcerol et al. (Obesity 2007), Nogueiras et al. (Endocrinology 2007), and others. Second, that obestatin slows gastric emptying — reported with variable replication. Third, that obestatin signals through the orphan G-protein-coupled receptor GPR39 — contested by Lauwers et al., Holst et al., Tremblay et al., and others, who reported that obestatin does not bind or activate GPR39 in their assays. GPR39 was subsequently deorphanized as a zinc-sensing GPCR, with no validated obestatin pharmacology at the receptor in independent laboratories. If there is a true obestatin receptor distinct from GPR39, it has not been definitively identified. Some authors have proposed that obestatin signals through a receptor system involving glucagon-like peptide-1 receptor (GLP1R) on pancreatic beta cells, based on the cytoprotective effects observed by the Ghigo/Granata group in Turin. Others have reported obestatin activity at the cardiac and vascular level through unidentified receptors. The lack of a validated cognate receptor is one of the clearest signals that obestatin biology is incomplete. Functional findings that have been replicated include modest gastrointestinal motility effects (with directional inconsistencies), central inhibition of drinking behavior in rats (Samson, White, Price, and Ferguson, Am J Physiol 2007), cytoprotective effects on isolated pancreatic beta cells and islet preparations in some models, and cardiovascular effects in ex vivo preparations. Effects on sleep, anxiety, and stress responses have been reported with variable replication. The honest summary is that obestatin produces measurable effects in some assay systems, but no single in vivo physiological role has been replicated cleanly enough across independent laboratories to constitute a settled mechanism.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Obestatin:

• 01Whether obestatin has any consistent effect on food intake or body weight in rodents — the original 2005 finding that drove the field has not been replicated by independent laboratories, and no consensus on the directional effect (or absence of effect) has emerged in twenty years.
• 02The molecular identity of the obestatin receptor — the original GPR39 claim has been contested, no replacement receptor has been definitively established, and obestatin's mechanism of action at the molecular level is unresolved.
• 03Whether the modestly more reproducible findings on obestatin (gastrointestinal motility, central drinking inhibition, beta-cell cytoprotection, cardiovascular ex vivo effects) reflect direct obestatin signaling, off-target effects, or experimental artifacts.
• 04The physiological role of obestatin in human biology — circulating concentrations and obestatin/ghrelin ratios have been measured in many disease states, but the absence of a clear physiological function makes interpretation of these measurements challenging.
• 05Whether obestatin processing from preproghrelin is regulated independently of ghrelin processing, and whether GOAT-mediated octanoylation of ghrelin influences the parallel production of obestatin from the same precursor.
• 06Whether selective obestatin-pathway pharmacology — if a true cognate receptor were identified — could deliver any of the originally proposed therapeutic effects (anti-obesity, beta-cell cytoprotection, cardiovascular protection) in humans.
• 07Whether the obestatin controversy itself, as a case study in peptide-endocrinology reproducibility, holds methodological lessons applicable to other novel-hormone discovery claims.

Forms & Administration

Obestatin is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic obestatin (typically the human 23-residue C-terminally amidated form) for in vitro receptor binding and signaling assays, ex vivo tissue pharmacology, and intracerebroventricular, intraperitoneal, or subcutaneous administration in animal models. The translational program that the original 2005 Science paper appeared to launch did not materialize because the central food-intake findings were not replicated, and no selective obestatin-pathway agonist or antagonist has been developed at clinical scale. Compounded obestatin from peptide marketplaces has no validated clinical use.

Common Questions

Who Obestatin Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for obestatin because no obestatin product has been clinically developed and the underlying receptor pharmacology is unsettled. Theoretical interactions are difficult to articulate in the absence of a validated cognate receptor: the original GPR39 identification has been contested, and no replacement receptor has been established. Reported effects on pancreatic beta cells could in principle interact with diabetes medications (insulin, sulfonylureas, GLP-1 agonists), but the underlying biology is not robust enough to support any specific drug-interaction prediction. Effects on gastrointestinal motility have been reported with variable replication and could theoretically interact with prokinetics or anticholinergic agents — again, the biology is not settled enough to ground any specific guidance. The most honest framing is that obestatin's drug-interaction profile cannot be characterized when its physiological role is itself disputed, and exogenous obestatin exposure outside research settings cannot be justified on the current evidence base.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions